Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F15%3A%230000214" target="_blank" >RIV/26475821:_____/15:#0000214 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=69dded53-c3d6-4118-9ac3-bd909db6632c&cKey=9e0bf2e1-f96e-4102-ba2a-83a65a14c435&mKey=" target="_blank" >http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=69dded53-c3d6-4118-9ac3-bd909db6632c&cKey=9e0bf2e1-f96e-4102-ba2a-83a65a14c435&mKey=</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers

Popis výsledku v původním jazyce

Poster describing ctDNA monitoring. Detection of circulation tumor DNA (ctDNA) in plasma has become a viable option for non-invasive monitoring of patients. Also termed ,,liquid biopsy? the approach is applicable for pre-diction of response and prediction of resistance to biological therapy (1, 2). Various techniques have been used for ctDNA detection, frequently employing clonal amplification on a digital PCR format (3) with limits of detection (LOD) below 0.01% of mutant alleles. However, these techniques suffer from high complexity, expensive instrumentation, and a considerable cost per sample. We hereby present a simple low-cost alternative that is implementable to routine ctDNA testing. DCE is a simple technique applicable for detection of ctDNA in cancer patients without a need for costly hardware/software equipment. The detection rates are 10 - 15% lower compared to the dedicated dPCR techniques,however, the method requires ca 100x less input DNA, the cost per patient is about 1

Název v anglickém jazyce

Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers

Popis výsledku anglicky

Poster describing ctDNA monitoring. Detection of circulation tumor DNA (ctDNA) in plasma has become a viable option for non-invasive monitoring of patients. Also termed ,,liquid biopsy? the approach is applicable for pre-diction of response and prediction of resistance to biological therapy (1, 2). Various techniques have been used for ctDNA detection, frequently employing clonal amplification on a digital PCR format (3) with limits of detection (LOD) below 0.01% of mutant alleles. However, these techniques suffer from high complexity, expensive instrumentation, and a considerable cost per sample. We hereby present a simple low-cost alternative that is implementable to routine ctDNA testing. DCE is a simple technique applicable for detection of ctDNA in cancer patients without a need for costly hardware/software equipment. The detection rates are 10 - 15% lower compared to the dedicated dPCR techniques,however, the method requires ca 100x less input DNA, the cost per patient is about 1

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14383" target="_blank" >NT14383: Využití volné nádorové DNA jako nového cíle pro minimálně-invazivní diagnostiku a zpřesnění molekulární klasifikace kolorektálních nádorů.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů